Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Advanced Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Advanced Carcinoma cohort.

Asset / SponsorPhaseRating
TIPIRACIL
Academic and Community Cancer Research United
Phase 2B
Palbociclib
Academic and Community Cancer Research United
Phase 2B
Trifluridine
Academic and Community Cancer Research United
Phase 2B
Binimetinib
Academic and Community Cancer Research United
Phase 2B
[68ga]ga-nota-t4
RenJi Hospital
Phase 2/3CCC

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →